Data from the TRAILBLAZER-ALZ 2 long-term extension (LTE) study demonstrated that donanemab (Kisunla, Eli Lilly and Company) continues to deliver meaningful benefits that increase over 3 years, especially when started early, with a manageable safety profile.

“There was a 27% reduced risk of progression if you were started initially in the trial versus delayed in the trial,” reported study investigator Mark Mintun, MD, group vice president of Neuroscience Research & Development at Eli Lilly and Company.

The core TRAILBLAZER-ALZ 2 study results were presented 2 years ago at the Alzheimer’s Association International Conference (AAIC) and simultaneously published in JAMA .

The most recent results were presented on July 30 at the AAIC 2025.

Ongoing Disease-Modifying Effects

Participan

See Full Page